Search results

    Search results

    Show all results for ""
    Can not find any results or suggestions for "."

    Search tips

    • Make sure there are no spelling errors
    • Try different search terms or synonyms
    • Narrow your search for more hits

    How can we help?

    Contact Us

    Find Employees

    University of Skövde, link to startpage

    Search results

      Search results

      Show all results for ""
      Can not find any results or suggestions for "."

      Search tips

      • Make sure there are no spelling errors
      • Try different search terms or synonyms
      • Narrow your search for more hits

      How can we help?

      Contact Us

      Find Employees

      University of Skövde, link to startpage

      Obesity and androgen excess in women – adiponectin as a new treatment option

      Research Group Translational Medicine TRIM
      Resarch Environment DHEAR

      Quick Facts

      Full project name

      Elevated levels of adiponectin may protect against polycystic ovary syndrome (PCOS)-related behavioral, metabolic and reproductive disturbances in mice Effects of adiponectin on gestational diabetes, placenta function and fetal growth The development of a PCOS-like drosophila fly model

      Duration

      January 2019 – December 2021

      Funding and collaboration

      Magnus Bergvalls stiftelse, Handlanden Hjalmar Svenssons forskningsfond, KVVS, The Adlerbertska Foundations, Torvald och Britta Gahlins stiftelse, University of Skövde, University of Gothenburg, Karolinska Institutet

      We focus on the molecular link between androgen excess and the development of reproductive disorders, obesity, and type-2 diabetes in females. Our overall aim is to investigate new treatments and identify the underlying mechanisms that improves or protect against the development of diabetes and decreased fertility. My line of research has evolved from more than 10 years of experience in whole-animal physiology studies involving endocrinology, metabolism and re-production.

      Obesity decreases fertility outcomes and increases the risk of developing gestational diabetes. Women with polycystic ovary syndrome (PCOS) also have impaired fertility and increased risk of developing obesity and diabetes. Mothers with PCOS, obesity or gestational diabetes frequently deliver babies born large or small for gestational age, who are susceptible to develop metabolic, reproductive and behavioral dysfunction later in life. We have published similar findings in mice where diet-induced obesity and androgen exposure during pregnancy cause reproductive, behavioral and metabolic dysfunction in offspring.

      Adiponectin secreted from adipose tissue improves insulin sensitivity and whole-body metabolism but its role in reproductive function and behavior is under explored. In a recent study we show that adiponectin overexpression prevents the development of metabolic disorders in PCOS-like mice but have only minor effects on reproductive functions. Adiponectin act on the placenta during pregnancy and this fact allows for the interesting possibility that adiponectin can exert endocrine effects on the developing fetus and protect against the effects of obesity and androgen exposure on the offspring. Therefore, we aim to test the hypothesis that elevated levels of adiponectin affects fertility, prevents the development of gestational diabetes and thereby protects against fetal overgrowth by preventing excess nutrient and androgen transport to the fetus,

      which in turn will prevent the development of metabolic, reproductive and behavioral alterations.

      During pregnancy women with PCOS display high circulating androgen levels that may affect the fetus and increase the risk of mood disorders. Over 60% of women with PCOS are diagnosed with at least one psychiatric disorder. The aim is to deeper understand adiponectin’s effects on reproductive functions, gestational diabetes and behavioral effects in the offspring. Our long-term goal is to identify an adiponectin-based therapy that improves offspring´s health and reduces the need of ovulation induction and insulin sensitizing drugs in obese and women with polycystic ovary syndrome (PCOS).

      Project leader

      Associate Professor of Biomedicine

      Participating Researchers

      Published: 1/23/2020
      Edited: 1/23/2020
      Responsible: webmaster@his.se